Literature DB >> 31793849

Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.

Jia-Yan Huang1, Jia-Wu Li1, Qiang Lu1, Yan Luo1, Ling Lin1, Yu-Jun Shi1, Tao Li1, Ji-Bin Liu1, Andrej Lyshchik1.   

Abstract

Background American College of Radiology contrast agent-enhanced US Liver Imaging Reporting and Data System (CEUS LI-RADS) was developed to improve the accuracy of hepatocellular carcinoma (HCC) diagnosis at contrast agent-enhanced US. However, to the knowledge of the authors, the diagnostic accuracy of the system in characterization of liver nodules 20 mm or smaller has not been fully evaluated. Purpose To evaluate the diagnostic accuracy of CEUS LI-RADS in diagnosing HCC in liver nodules 20 mm or smaller in patients at risk for HCC. Materials and Methods Between January 2015 and February 2018, consecutive patients at risk for HCC presenting with untreated liver nodules 20 mm or less were enrolled in this retrospective double-reader study. Each nodule was categorized according to the CEUS LI-RADS and World Federation for Ultrasound in Medicine and Biology (WFUMB)-European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) criteria. Diagnostic performance of CEUS LI-RADS and WFUMB-EFSUMB characterization was evaluated by using tissue histologic analysis, multiphase contrast-enhanced CT and MRI, and imaging follow-up as reference standard and compared by using McNemar test. Results The study included 175 nodules (mean diameter, 16.1 mm ± 3.4) in 172 patients (mean age, 51.8 years ± 10.6; 136 men). The sensitivity of CEUS LR-5 versus WFUMB-EFSUMB criteria in diagnosing HCC was 73.3% (95% confidence interval [CI]: 63.8%, 81.5%) versus 88.6% (95% CI: 80.9%, 94%), respectively (P < .001). The specificity of CEUS LR-5 versus WFUMB-EFSUMB criteria was 97.1% (95% CI: 90.1%, 99.7%) versus 87.1% (95% CI: 77%, 94%), respectively (P = .02). No malignant lesions were found in CEUS LR-1 and LR-2 categories. Only two nodules (of 41; 5%, both HCC) were malignant in CEUS LR-3 category. The incidences of HCC in CEUS LR-4, LR-5, and LR-M were 48% (11 of 23), 98% (77 of 79), and 75% (15 of 20), respectively. Two of 175 (1.1%) histologic analysis-confirmed intrahepatic cholangiocarcinomas were categorized as CEUS LR-M by CEUS LI-RADS and misdiagnosed as HCC by WFUMB-EFSUMB criteria. Conclusion The contrast-enhanced US Liver Imaging Reporting and Data System (CEUS LI-RADS) algorithm was an effective tool for characterization of small (≤20 mm) liver nodules in patients at risk for hepatocellular carcinoma (HCC). Compared with World Federation for Ultrasound in Medicine and Biology-European Federation of Societies for Ultrasound in Medicine and Biology criteria, CEUS LR-5 demonstrated higher specificity for diagnosing small HCCs with lower sensitivity. Published under a CC BY 4.0 license. See also the editorial by Crocetti in this issue.

Entities:  

Year:  2019        PMID: 31793849     DOI: 10.1148/radiol.2019191086

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  18 in total

Review 1.  Using LI-RADS With Contrast-Enhanced Ultrasound.

Authors:  Shuchi K Rodgers; David T Fetzer; Yuko Kono
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-04-13

2.  Tumor size-based validation of contrast-enhanced ultrasound liver imaging reporting and data system (CEUS LI-RADS) 2017 for hepatocellular carcinoma characterizing.

Authors:  Jia-Min Pan; Wei Chen; Yan-Ling Zheng; Mei-Qing Cheng; Dan Zeng; Hui Huang; Yang Huang; Xiao-Yan Xie; Ming-De Lu; Ming Kuang; Hang-Tong Hu; Li-Da Chen; Wei Wang
Journal:  Br J Radiol       Date:  2021-10-01       Impact factor: 3.629

3.  High frame-rate contrast enhanced ultrasound (HIFR-CEUS) in the characterization of small hepatic lesions in cirrhotic patients.

Authors:  F Giangregorio; M Garolfi; E Mosconi; L Ricevuti; M G Debellis; M Mendozza; C Esposito; E Vigotti; D Cadei; D Abruzzese
Journal:  J Ultrasound       Date:  2022-10-13

Review 4.  Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Mirella Fraquelli; Tin Nadarevic; Agostino Colli; Cristina Manzotti; Vanja Giljaca; Damir Miletic; Davor Štimac; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2022-09-02

Review 5.  Contrast-enhanced ultrasound (CEUS) in HCC diagnosis and assessment of tumor response to locoregional therapies.

Authors:  John R Eisenbrey; Helena Gabriel; Esika Savsani; Andrej Lyshchik
Journal:  Abdom Radiol (NY)       Date:  2021-04-07

6.  Can Risk Stratification Based on Ultrasound Elastography of Background Liver Assist CEUS LI-RADS in the Diagnosis of HCC?

Authors:  Jiawu Li; Wenwu Ling; Shuang Chen; Lulu Yang; Lin Ma; Qiang Lu; Yan Luo
Journal:  Front Oncol       Date:  2021-04-30       Impact factor: 6.244

7.  Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Authors:  Jie Yang; Ya-Han Zhang; Jia-Wu Li; Ying-Yu Shi; Jia-Yan Huang; Yan Luo; Ji-Bin Liu; Qiang Lu
Journal:  World J Gastroenterol       Date:  2020-12-14       Impact factor: 5.742

Review 8.  Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound.

Authors:  Junghoan Park; Jeong Min Lee; Tae-Hyung Kim; Jeong Hee Yoon
Journal:  Clin Mol Hepatol       Date:  2021-12-27

9.  Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?

Authors:  Jia-Yan Huang; Jia-Wu Li; Wen-Wu Ling; Tao Li; Yan Luo; Ji-Bin Liu; Qiang Lu
Journal:  World J Gastroenterol       Date:  2020-07-21       Impact factor: 5.742

10.  Real-life assessment of standardized contrast-enhanced ultrasound (CEUS) and CEUS algorithms (CEUS LI-RADS®/ESCULAP) in hepatic nodules in cirrhotic patients-a prospective multicenter study.

Authors:  D Strobel; E-M Jung; M Ziesch; M Praktiknjo; A Link; C F Dietrich; C Klinger; M Schultheiß; D Jesper; B Schellhaas
Journal:  Eur Radiol       Date:  2021-04-15       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.